What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.
ASJC Scopus subject areas
- Health(social science)
- Health, Toxicology and Mutagenesis
- Health Information Management